ATYR Stock Analysis: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.85
0.07 (9.08%)
▲
5d:
+6.44%
30d:
-11.37%
90d:
+14.2%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
ATYR is down 3.9% this week, but smart money is accumulating calls. Top strike: $1 2026-05-15 with 4,399 OI. Call ratio: 100% View Scanner →
Strength: 7.0/10
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ATYR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ATYR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.85, which is considered fair relative to its 30-day fair value range of $0.80 to $0.96.
Technical Outlook: Technically, ATYR is in a uptrend. The price is approaching resistance at $0.86. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.36 (+412.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATYR is in a uptrend. The price is approaching resistance at $0.86. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.36 (+412.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$0.80 -
$0.96
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.1%)
- BULLISH: Trading 412.1% below Wall St target ($4.36)
Fair Price Analysis
30-Day Fair Range
$0.80 -
$0.96
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$0.86
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.04
Wall Street Target
$4.36
(+412.1%)
Share & Embed Analysis
Last updated: April 02, 2026 6:05 AM ET
Data refreshes hourly during market hours. Next update: 7:05 AM
Data refreshes hourly during market hours. Next update: 7:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
2
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill Marie Broadfoot
SELL
1558 shares
2026-02-04
Nancy Denyes
SELL
1118 shares
2026-02-04
Sanjay Shukla
SELL
3745 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 52 HOLD |
